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Abstract  
The 2019 coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2), has swept the globe. Based on a retrospective analysis of SARS and 
influenza data from China and around the world, we suggest that fungal co-infections associated with 
global COVID-19 may be missed or misdiagnosed. Although there are few publications, patients with 
COVID-19, especially severely ill or immunocompromised patients, are more likely to develop invasive 
mycoses. Aspergillus and Candida infections in patients with COVID-19 will require early detection by 
comprehensive diagnostic intervention (histopathology, direct microscopy, culture, (Arabian: 2004, 
Tilavberdiev: 2016) -β-D-glucan, galactomannan, and PCR assays) to ensure effective treatment. We 
consider it appropriate to assess risk factors, types of invasive mycoses, strengths and weaknesses of 
diagnostic methods, clinical conditions, and the need for standard or individual treatment. 
 




The global popularity of COVID-19 and the possibility of co-infection with fungal infections. As 
a person-to-person transmitted disease, Coronavirus Disease 2019 (COVID-19) caused by coronavirus 2 
(SARS-CoV-2) severe acute respiratory syndrome has become a global public health emergency (Zhou: 
2020, Gorbalenya: 2020). By May 18, 2020, COVID-19 had rapidly spread to 212 countries and caused 
nearly 5 million laboratory-confirmed cases and more than 310,000 deaths worldwide. Similar to SARS-
CoV and Middle East Respiratory Syndrome Coronavirus (MERS-CoV), SARS-CoV-2 is responsible for 
lower respiratory tract infections and can cause Acute Respiratory Distress Syndrome (ARDS) (Wang: 
2019). In addition to diffuse alveolar lesions with pronounced inflammatory exudation, patients with 
COVID-19 always have immunosuppression with a decrease in CD4 + T and CD8 + T cells (Yang: 
2019). In critically ill patients, especially in patients who were admitted to the intensive care unit (ICU) 
and who required mechanical ventilation, or who were in the hospital for a longer time, even up to 50 
days, were more likely to develop co-morbid fungal infections (Yang X: 2020). Therefore, it is important 
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to note that patients with COVID-19 may develop further fungal infections in the middle and late stages 
of the disease, especially in severe form (Gangneux: 2020). 
 
Discussion 
Epidemiology of concomitant fungal infections in patients with COVID-19. 
 
Unfortunately, very few articles have reported co-occurring fungal infections, not only that some 
studies have not provided detailed information on the pathogens. Nevertheless, patients with COVID-19 
were found, especially seriously ill or immunocompromised, who had concomitant fungal infections (Guo 
L: 2019). In China, Chen et al. performed fungal culture on all 99 COVID-19 patients upon admission 
and found five (5%, 5/99) cases of fungal infection, including one case of Aspergillus flavus, one case of 
Candida glabrata and three cases of C. albicans (Chen: 2019). Young et al. Found concomitant fungal 
infection in three of 52 critically ill patients (3/52, 5.8%), including A. flavus, A. fumigatus, and C. 
albicans (Yang X: 2020). Other Chinese studies have found a higher percentage of secondary infections 
(8-15%) in patients with COVID-19, but it is unclear whether this is a bacterial or fungal infection 
(Huang: 2019, Ruan: 2020). In addition, one study mentioned that 2.8% (31/1099) of patients were 
treated with antifungal drugs, including 1.9% (18/926) of mild patients and 7.5% (13/173) of patients 
with a severe form, but there is no etiological evidence of fungal coinfection. (Guan: 2020) 
 
Tilavberdiev Sh.A., Klimko N.N., Denning D.V. (2016) studying the use of the life program 
model to assess the prevalence of severe and chronic mycotic diseases in the Republic of Uzbekistan, note 
that in 2014 in the Republic of Uzbekistan the number of patients with severe and chronic mycotic 
diseases was 535 640 people. According to the results of the study, the author established a significant 
prevalence of mycoses in the Republic of Uzbekistan, which necessitates a deeper study of their 
epidemiological and clinical features and the improvement of preventive measures (Tilavberdiev: 2016). 
 
Klimko N.N. et al. note that some changes in the chemical composition of sebum (a decrease in 
the squalene / triglyceride ratio) promotes hypercolonization of the skin by yeast-like fungi and their 
transition to a pathogenic - mycelial form (Zhou: 2020). 
 
Another study mentioned that in 149 cases, patients did not receive antifungal drugs (Yang W: 
2019). A German study found that invasive pulmonary aspergillosis (IPA) associated with COVID-19 
was found in five (26.3%) of 19 consecutive critically ill patients with moderate to severe ARDS [14]. In 
the Netherlands, 31 ICU patients had six patients (19.4%) with putative IPA, of which five were 
identified as A. fumigatus (Van Arkel: 2020). In addition, among the first 5 well-described French 
COVID-19 patients, an elderly, critically ill male was found to be coinfected with A. flavus by culture of 
tracheal aspirates (Lescure: 2020). 
 
Abandoned fungal coinfection in patients with COVID-19 based on assumptions related with 
SARS and flu. 
 
Studies have shown that SARS-CoV and SARS-CoV-2 belong to the same species and have 
similar prevalence, biological and clinical characteristics (Peeri: 2020). Looking back at SARS in 2003, it 
was found that the incidence of fungal infections in SARS patients was 14.8–27%, which was even higher 
in critically ill patients, up to 21.9–33% (Zhang Y: 2003). The main cause of death in SARS patients was 
fungal infection, accounting for 25–73.7% of all causes of death (Li: 2003). In addition, in recent decades, 
more and more reports of severe influenza pneumonia leading to ARDS complicated by fungal infection 
have been published (Thevissen: 2020). One study found that IPA was diagnosed in 83 (19%) of 432 
patients hospitalized with influenza, which was higher in immunocompromised patients (32%), and in the 
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case of IPA, mortality increased from 28% to 51% (Schauwvlieghe: 2018). However, as far as fungal 
coinfection in COVID-19 patients is concerned, only a few studies have reported this and may have been 
neglected. Clinically, many COVID-19 patients did not have a sputum fungus assessment in the 
beginning, and the fungus is difficult to detect with fungal sputum culture alone (Guan: 2020). As the 
disease worsens, severe respiratory symptoms can be easily attributed to COVID-19, at best considering 
co-infection with bacteria or even mycoplasma (Chaturvedi: 2018), which usually leads to timely 
antibiotic use, and the diagnosis of a fungal infection is always delayed or ignored. Based on the 
experience of SARS in 2003 and cases of invasive aspergillosis combined with severe influenza, it is 
critically important to pay attention to the likelihood of COVID-19 accompanied by fungal infections. 
 
Clinical and Diagnostic Perspective of COVID-19, associated with fungal coinfection. 
 
With the ongoing COVID-19 pandemic, more and more experts are learning about joint fungal 
infections. The French High Council of Public Health has recommended systematic screening for fungal 
pathogens in patients with COVID-19 (Gangneux: 2020). Academician Lanjuan Li and her colleagues, 
who have accumulated experience in the severe treatment of COVID-19, reminded clinicians to focus on 
fungal infections in patients, especially those who are severe or immunocompromised (Xu K: 2020). At 
an early stage of the disease or in extrapulmonary fungal infections, atypical chest imaging may occur. 
 
Therefore, in critically ill patients, it is necessary to observe for fungal pathogens, including (i) 
etiological examination: direct microscopy and culture; (Ii) histopathology; (Iii) serology: antigen and 
antibody, detection of (1,3) -β-D-glucan (BDG) (Lahmer: 2017) and galactomannan (GM) in serum 
should also be tested in suspicious patients, while bronchoalveolar lavage fluid (BALF )) and sampling of 
tracheal aspirate (TA) for inoculation and biomarker testing should be carried out in a well-protected 
environment due to the risk of aerosol spread and infection of health-care workers (Prattes: 2020); (Iv) 
PCR-based methods. If necessary, polymerase chain reaction (PCR) and molecular identification in real 
time can be performed to identify pathogens (Hage: 2019). Once the pathogen has been identified, an 
antifungal susceptibility test (AST) can be performed to select susceptible antifungal agents. If AST 
cannot be performed, it should be treated empirically. The main fungal pathogens of co-morbid fungal 
infections in patients with severe COVID-19 are Aspergillus and Candida. Other infrequent opportunistic 
fungi that cause lung infections, such as Mucor and Cryptococcus, must also be considered. 
 
Invasive aspergillosis (IA). Aspergillus species can be an important cause of life-threatening 
infection in COVID-19 patients, especially those with high risk factors. Potential risk factors for patients 
include GC use, long-term neutropenia, chronic obstructive pulmonary disease (COPD), allogeneic 
hematopoietic stem cell transplantation (allo-HSCT) (Miceli: 2017), solid organ transplant (SOT) 
(Fishman: 2020), hereditary immunodeficiencies, hematopoietic disorders, malignant neoplasms (HM), 
cystic fibrosis (CF) (Poli: 2020), etc. The diagnosis of IA requires microbiological and or 
histopathological findings, although specimen collection is challenging for many patients because lung 
biopsy may be contraindicated in patients with clotting disorders or severe respiratory failure (Van Arkel: 
2020). Histopathological examination is mainly based on the detection of specific fungal patches on the 
lung fluid or tissue when a fungal infection is suspected and may reveal the characteristic acute angular 
branching septa of Aspergillus spp., As well as Grocott-Gomori methenamine silver (GMS) and periodic 
acid staining, staining fixed tissue Schiff (PAS) would be beneficial, while Aspergillus spp is difficult to 
distinguish from other filamentous fungi such as Fusarium spp. and Scedosporium spp. (Blot: 2012). 
Therefore, definitive confirmation by culture or non-culture method should be obtained, including (i) 
direct microscopic examination using optical brightener, Calcofluor or Blankophor methods, which can 
increase the sensitivity and specificity for the detection of Aspergillus-like traits; (Ii) culturing on fungal-
specific medium at 37 ° C for 2-5 days, if positive, Aspergillus morphological traits can be identified 
under a microscope or DNA sequencing can be used in reference laboratories to accurately identify 
species, but usually yields cultures are low, and a negative result does not exclude the diagnosis of IA; 
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(Iii) molecular assays targeting ribosomal DNA (rDNA) sequences can also be used to detect Aspergillus 
in tissues or BALF, especially to detect Aspergillus spp. and mutations of resistance to CYP51A in A. 
fumigatus, although these methods have not been standardized or limited by laboratory conditions or 
validated commercial reagents in some countries (Patterson: 2016); (Iv) Serum and BALF GM testing is 
also recommended as an early and accurate marker using less invasive diagnostic methods, especially in 
neutropenic patients, with the benefits of fewer trauma and time savings, although sometimes this test in 
blood samples is less sensitive. than cultured respiratory specimens (Hage: 2019). 
 
Treatment recommendations can be supported by updated guidelines from the Society of 
Infectious Diseases of America 2016, according to which the prevention, therapeutic treatment, 
combination and alternative treatment of Aspergillus infection received more detailed recommendations 
(Patterson: 2016). Typically, drugs recommended for the treatment and prevention of IA include triazoles 
(itraconazole, voriconazole, posaconazole, ezaconazole), amphotericin B and its liposomes, and 
echinococins (micafungin or carpofening). Most patients can choose triazole drugs for the treatment of 
AI, however, therapeutic drug monitoring (TDM) is recommended and interactions between azoles and 
other drugs should be fully considered. 
 
Invasive candidiasis (IC). For patients with severe COVID-19 who are more likely to be treated 
with broad-spectrum antibiotics, parenteral nutrition and invasive examinations, or patients with 
prolonged neutropenia and other immune deficiencies, the risk of contracting Candida species may be 
significantly increased. (Clancy: 2018). Diagnosis of IC depends on culture methods, including culture of 
blood or other specimens collected under sterile conditions, which are generally considered the gold 
standards for IC, and diagnostic tests not related to culture, including tests for mannan and anti-mannan 
IgG, antibodies to C. albicans from germ tube (CAGTA), BDG. and PCR-based assays, which are now 
included in clinical practice as an adjunct to cultures (Ibanez-Martinez: 2017). Basically, there are two 
drawbacks to blood culture, on the one hand, the blood culture time is long because the average time for a 
positive alarm is 2–3 days (range 1 to ≥ 7 days), plus the duration of the ID and sensitivity test is 4 to 6 
days, on the other hand, it is less sensitive than PCR, with a much lower detection limit when Candida 
concentration is ≤ 1 CFU / ml, and cannot detect candidiasis in extremely low concentrations, intermittent 
candidiasis, or deep Candida infection that has not been trapped into the blood. Therefore, several non-
cultural diagnostic tests are recommended, but there is also widespread uncertainty about their usefulness 
in clinical practice (Clancy: 2018). β-D-glucan (BDG) is a major component of the cell wall of Candida 
and most pathogenic fungi, with the exception of Cryptococcus, Blastomyces and Mucorales species, 
which is widely used in clinical practice and is well recommended for detection in serum, but cannot 
distinguish Candida from other fungi (Hage: 2019). In addition, IgG mannan and anti-mannan tests, 
CAGTA are used in many European centers, and higher sensitivity and specificity are observed when 
combined with the mannan / anti-mannan assay (Mikulska: 2010). 
 
There are promising PCR tests, including multiplex PCR platforms, while there are some 
limitations due to the lack of multicenter validation of assay performance, so there are no FDA approved 
PCR tests for Candida, but there are commercial and proprietary tests that are widely available. In 
addition, T2 magnetic resonance can also be used to enhance and detect Candida DNA, but its potential 
for early diagnosis of candidemia remains unclear. MALDI-TOF technology is available in more 
hospitals with the greatest advantage of its speed, requiring no more than 5 minutes to identify a 
microorganism in isolated colonies, even researchers have developed protocols for identifying yeast 
directly from bottles with positive blood cultures for half an hour without performing subcultures (Ibanez-
Martinez: 2017). In general, not only must the benefits of combining culture and non-culture methods be 
fully understood, but also, clinicians must take into account the IC types, the advantages and limitations 
of each study method, and the context of the clinical setting in order to make a reasonable interpretation. 
In addition, a susceptibility test is recommended for all bloodstream Candida isolates and other clinically 
relevant Candida isolates, especially C. glabrata or C. parapsilosis. 
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Treatment recommendations can be supported by the updated Infectious Disease Society of 
America recommendations from 2016, according to which therapeutic and alternative drugs for candidal 
infection received more detailed recommendations (Pappas: 2016). As a rule, patients with suspected or 
confirmed CI should receive echinocandin (caspofungin, micafungin, and anidulafungin), azoles 
(fluconazole, voriconazole, itraconazole), and amphotericin B and its liposomes, moreover, TDM should 
be used for azoles. optimize efficacy and limit toxicity. 
 
Invasive mucormycosis. Patients with COVID-19 with trauma, diabetes mellitus, intake of GC, 
malignant neoplasms (HM), prolonged neutropenia, allo-HSCT, SOT are more likely to develop 
mucormycosis (Cornely: 2019). The suspicion of mucormycosis is usually based on direct microscopy or 
fluorescent whiteners from clinical specimens such as sputum, BALF, and skin lesions in which 
Mucorales hyphae do not have septa or small septa with variable widths of 6–16 µm. To confirm the 
diagnosis, unpigmented hyphae showing tissue invasion should be shown on tissue sections stained with 
hematoxylin-eosin (HE), PAS, or GMS (Skiada: 2018). For genus and species identification, specimen 
cultivation is strongly recommended, as well as AST. Moreover, it is recommended to cultivate at 30 ° C 
and 37 ° C separately to obtain cottony white or grayish-black colonies, and then morphologically 
identify fungi or DNA sequencing based on barcode genes such as 18S, ITS, 28s, or rDNA. MALDI-TOF 
identification is moderately supported because it depends mainly on internal databases, and many 
laboratories do not have this capability (Dadwal: 2018). In addition, the detection of fungal DNA in 
serum, as well as in other body fluids, even in paraffin-embedded tissue, is promising, however, due to a 
lack of standardization, it is only supported with moderate efficacy. 
 
Treatment recommendations can be supported by the 2019 global guidelines for the diagnosis and 
treatment of mucormycosis by the European Confederation for Medical Mycology (ECMM) and the 
Consortium for Mycosis Education and Research, which provided more detailed guidance on therapeutic 
and alternative drugs for mucormycosis (Cornely: 2019). It generally strongly supports early, complete 
surgical treatment of mucormycosis whenever possible, in addition to systemic antifungal treatment. 
Patients with neutropenia, patients with graft versus host disease, or those with a high-risk factor may be 
advised to use posaconazole for primary prophylaxis. Amphotericin B Lipid Complex, Amphotericin B 
Liposomal and Posaconazole Oral Suspension are considered first-line antifungal monotherapy, while 
isavuconazole is strongly supported as a therapeutic agent. There is no conclusive evidence to guide the 
use of antifungal combination therapy of polyenes and azoles or polyenes with echinocandins. 
 
Invasive cryptococcosis. Patients with COVID-19, with human immunodeficiency virus (HIV) 
infection with CD4 + T-lymphocyte count <200 cells / μL, allo-HSCT, SOT or other immune disorders 
are susceptible to cryptococcosis, which manifests itself predominantly as meningoencephalitis 
(Setianingrum: 2019) ... Considering the difficulties associated with the diagnosis of cryptococcosis and 
the identification of Cryptococcus species, including C. neoformans and C. Gattii. The diagnosis of 
cryptococcosis is usually based on a combination of clinical and laboratory confirmation. The following 
methods are used to confirm infection: culture, direct microscopy, histopathology, serology, and 
molecular detection. To diagnose cryptococcosis, a sample of cerebrospinal fluid (CSF) is mixed with 
India Ink and under a microscope, Cryptococcus spp. with narrow kidneys. Encapsulated yeast is 
commonly found. Culture samples should be plated on Sabouraud Dextrose Agar at 30 ° C for 7 days 
under aerobic conditions and observed daily. Moreover, cultures from patients receiving systemic 
antifungal therapy may take longer to grow. Cryptococcus looks like slimy, creamy colonies. 
Cryptococcus capsular polysaccharides can be detected and quantified in body fluids such as serum, 
cerebrospinal fluid, BALF or abnormal tissue. Three formats of cryptococcal antigen (CrAg) detection 
tests are currently available: latex agglutination test (LAT), enzyme-linked immunosorbent assay (EIA), 
and lateral flow immunoassay (LFA). These methods are rapid, sensitive and specific, but they are not 
standardized for respiratory specimens such as BAL fluid, pleural fluid, or sputum (Ibanez-Martinez: 
2017). Molecular detection of cryptococcus is required in certain situations where other diagnostic tools 
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have failed to confirm the diagnosis of cryptococcosis. These molecular methods include pan-fungal 
PCR, DNA sequencing for identification, multiplex PCR, isothermal amplification, and probe 
microarrays. Once a diagnosis of cryptococcosis is made, lumbar puncture and examination of 
cerebrospinal fluid (including antigen) are recommended for all patients (Gassiep:2018). Cryptococcus 
can spread to the central nervous system, causing cryptococcal meningitis. 
 
Treatment recommendations can be supported by the World Health Organization guidelines for 
the diagnosis, prevention and treatment of cryptococcal infection in HIV-infected adults, adolescents and 
children in 2018 (from: https://www.who.int/hiv/ pub / guidelines / cryptococcal disease / en /). Typically, 
the following is recommended as the preferred regimen: (i) an induction phase for amphotericin B and + 
flucytosine deoxycholate followed by fluconazole; alternatives: fluconazole + flucytosine or amphotericin 
B deoxycholate + fluconazole. (II) The phase of consolidation of fluconazole. (III) Maintenance (or 





Thus, by analyzing retrospective analyzes of SARS and influenza data in China and around the 
world, we hypothesize that co-occurring fungal infections associated with global COVID-19 may be 
overlooked or misdiagnosed. In addition, as a life-threatening infectious disease, COVID-19 patients 
exhibited overexpression of inflammatory cytokines and impaired cell-mediated immune response with 
decreased CD4 + T and CD8 + T cell counts, indicating its susceptibility to co-fungal infection. 
Moreover, COVID-19 patients with an immunocompromised condition such as prolonged neutropenia, 
HSCT, HA use, SOT, hereditary or acquired immunodeficiencies, and tumor are more likely to develop 
fungal coinfection. Here we have summarized updated diagnostic information (histopathology, direct 
microscopic examination, culture, (1,3) -β-D-glucan, galactomannan, PCR assays, MALDI-TOF 
technology, etc.) and recommendations for the treatment of invasive mycosis ... We believe that it is 
appropriate to assess risk factors, types of invasive mycosis, strengths and weaknesses of diagnostic 
methods, clinical parameters and the need for standard or individualized treatment of patients with 
COVID-19. Finally, a clinical outline (Figure 1) was provided to assist clinicians and laboratory experts 
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